• Research and Development

  Potential IPF Therapy PXS-5382A Shows Potential in Phase 1 Trial

  Posted by pulmonary-fibrosis-news-moderator on December 6, 2018 at 11:32 am

  Phase 1 data show that Pharmaxis’ second LOXL2 inhibitor, PXS-5382A, is safe and holds potential to treat fibrotic diseases, including IPF. Click here to find out more.

  Did you know about this potential treatment? What are your thoughts on it?

  pulmonary-fibrosis-news-moderator replied 5 years, 4 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply